Alex discusses the shortcomings of the Pfizer vaccine trial, highlighting the lack of older participants despite their higher risk. He emphasizes that the trial design prioritized speed and commercial interests over inclusivity. The conversation also touches on controversial views regarding vaccine distribution based on race and age, raising ethical questions about prioritization in public health.
